Moderna, Inc. (MRNA)
Moderna Stock Soars After First US Bird-Flu Death
Moderna (MRNA) shares jumped more than 10% to lead S&P 500 gainers Tuesday, a day after the first bird-flu death was reported in the U.S. The biotech company is developing a vaccine for H5N1.
Moderna among vaccine makers to surge on US bird flu death
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares surged alongside rival vaccine makers on Tuesday after news broke of the first human death related to the H5 bird flu strain in the US. America's Centers for Disease Control and Prevention (CDC) on Monday reported an elderly patient in Louisiana with underlying medical conditions had died from the disease.
Moderna Stock Jumps Amid Bird Flu Vaccine Hope After First U.S. Death
The company is one of a few drugmakers currently developing a vaccine for the illness, which is spreading rapidly through North America.
Moderna (MRNA) Rises But Trails Market: What Investors Should Know
In the latest trading session, Moderna (MRNA) closed at $42.18, marking a +0.43% move from the previous day.
Moderna: From Breakthrough COVID-19 Vaccines To Personalized Cancer Therapies
Moderna's partnership with Merck in personalized cancer therapies and promising Phase III trials support a speculative 'Buy' for long-term investors with high-risk tolerance. Despite a tough 2024, MRNA's pipeline reprioritization and $9 billion cash reserve position it for potential blockbuster products and revenue growth by 2028. Financial discipline has reduced cash burn and extended runway, with upcoming Phase III results in oncology and CMV expected to drive future profitability.
Moderna: 2025 Contrarian Play
Moderna ends 2024 as one of the worst-performing Nasdaq-100 stocks, but it presents a contrarian play for 2025 due to vaccine catalysts. The stock is down to $40 with a $15 billion market cap, despite having $3+ billion in revenue and a promising pipeline. Moderna's spending issue is a concern, but the potential of its CMV and cancer vaccines could significantly boost sales and justify current R&D expenses.
Moderna Stock Down 39% in Three Months: Buy the Dip or Wait?
Shares of MRNA have been declining after it lowered its long-term financial guidance. It has also pushed its breakeven point by another two years to 2028.
Is Moderna Stock a Buy?
Moderna's (MRNA 3.13%) wild success in the COVID-19 vaccine market has worn off. The company's revenue, earnings, and stock price have been moving in the wrong direction for the past three years, a period during which the biotech has lost 85% of its value.
3 Stocks That Could Turn $1,000 into $5,000 by 2030
A five-bagger in only five years? Any investor would love to buy such a stock.
Moderna, Inc. (MRNA) Piper Sandler 36th Annual Healthcare Conference (Transcript)
Moderna, Inc. (NASDAQ:MRNA ) Piper Sandler 36th Annual Healthcare Conference December 5, 2024 10:30 AM ET Company Participants Stephane Bancel - Chief Executive Officer Conference Call Participants Ted Tenthoff - Piper Sandler Ted Tenthoff Good morning, everyone. My name is Ted Tenthoff.
Moderna, Inc. (MRNA) 7th Annual Evercore ISI HealthCONx Conference - (Transcript)
Moderna, Inc. (NASDAQ:MRNA ) 7th Annual Evercore ISI HealthCONx Conference Call December 4, 2024 1:20 PM ET Company Participants Lavina Talukdar - Senior Vice President and Head of Investor Relations Conference Call Participants Cory Kasimov - Evercore ISI Cory Kasimov Good afternoon, everyone. I'm Cory Kasimov, one of the senior biotech analysts here at Evercore ISI.
Moderna: Optimistic Outlook Despite The Recent Sell-Off
Moderna's stock is undervalued, so I maintain a positive outlook with a $97 price target for next year. 3Q24 results show good COVID-19 revenue, cost efficiency, and a significant cash balance, but RSV vaccine sales underperformed. The pipeline includes promising next-gen COVID-19, RSV, flu, CMV, norovirus, and oncology drugs, with substantial revenue potential by 2027.
